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Background: Previous studies suggested that expression of cyclin-dependent kinase 5 (CDK5) may promote the
migration and invasion of human glioma cells. In this study, we aimed to evaluate the clinical value of CDK5 in
different grades of glioma in relation to Ki-67 labeling index (LI).
Methods: We firstly assessed by immunohistochemistry the expression of CDK5 in 152 glioma tissues and 16
normal brain tissues and further explored the relationship between CDK5 expression and other clinical features.
Results: The positive ratio of CDK5 in gliomas (57.2 %) was higher than that in normal brain tissues (12.5 %,
P = 0.001). Difference of CDK5 expression among four World Health Organization (WHO) grades was statistically
significant (P = 0.001). The significant differences of CDK5 expression were also observed between WHO I glioma
(34.8 %) and WHO III glioma (62.5 %), as well as WHO IV glioma (82.8 %; P = 0.026, P < 0.001, respectively).
Furthermore, Spearman’s rank correlation confirmed that CDK5 was positively correlated with the pathological grade of
glioma (r = 0.831, P < 0.001). The CDK5 expression was also positively correlated with Ki-67 LI (r = 0.347, P < 0.001).
Conclusions: The current result suggests that CDK5 may play an essential role in the tumorigenesis and
aggressiveness of gliomas.
Keywords: CDK5, Glioma, Immunohistochemistry, Clinical featuresBackground
Gliomas, the most frequent intracranial malignant
tumor, are categorized as grade I to grade IV based on
histological and clinicopathological criteria, as provided
by the World Health Organization (WHO) [1]. Gliomas
of grade I are often considered to be benign. They are
commonly curable with thorough surgical resection and
seldom have the possibility of evolving into higher-grade
lesions. However, gliomas of grade II or III demonstrate
the invasion and progression to higher-grade lesions
with a poor consequence. WHO grade IV gliomas, the
most aggressive form, have a dismal outcome [2]. During
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omas harbor valuable information for diagnosis, progno-
sis, or prediction, specifically comprising the combined
loss of chromosome arms 1p and 19q, TP53 mutation,
the incidence of isocitrate dehydrogenase 1 (IDH1) mu-
tation, and the amplification of epidermal growth factor
receptor (EGFR) and copy number aberrations of chro-
mosomes 7 and 10 [3–6].
Cyclin-dependent kinase 5 (CDK5), which is a proline-
directed serine/threonine kinase, expresses predominately
in mature neurons and is involved in neurite extension,
neuronal migration, and neuronal differentiation [7].
Cellular stress can induce the cleavage of p35 by the
Ca2+-dependent protease calpain to p25, which aberrantly
activates CDK5, thereby promoting the phosphorylation
of substrates implicated in neurodegeneration [8, 9]. Actu-
ally, elevated CDK5 expression has been detected in differ-
ent classes of cancers, such as lung, pancreatic,ticle distributed under the terms of the Creative CommonsAttribution License
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Previously, activity of CDK5 has been noted in oligoden-
drocytes [14]. Additionally, evidence points that CDK5-
mediated phosphorylation of PIKE-A (isoform A of
phosphatidylinositol 3-kinase enhancer), which is a novel
pro-oncogenic and antiapoptotic element that activates
protein kinase B (AKT) pathway and stimulates cell
growth, promotes cell migration and invasion in glioblast-
omas [15]. More recently, CDK5-induced p-PPARγ has
been reported to downregulate GFAP which preserves
shape and arbor of astrocyte processes contributing to the
cellular mechanical strength of the astrocyte [16]. These
aforementioned studies support the hypothesis that ex-
pression of CDK5 promotes the migration and invasion of
human glioma cells. To our knowledge, there has been no
study investigating the different expression of CDK5 be-
tween normal human brain and glioma tissues in a large
number of patients. Thus, the current study was to inves-
tigate the possible role of CDK5 in the tumorigenesis and
aggressiveness of glioma and emphasized the relationship
of CDK5 expression with Ki-67 labeling index (LI), which
represents the status of tumor cell proliferation.
Methods
Patients
This retrospective study included a total number of 152
glioma samples that were surgically resected from the
First Affiliated Hospital of the Guangxi Medical Univer-
sity (Nanning, Guangxi, China) during the period from
January 2008 until September 2013. The patients in the
current study included 106 males (69.7 %) and 46 fe-
males (30.3 %) with a mean age of 40.50 ± 16.6 (range,
7–75 years old). According to the classification criteria
of nervous system tumors (WHO, 2007), 23 cases were
WHO grade I as pilocytic astrocytomas, 44 cases were
grade II (including 21 cases of fibrillary astrocytoma, 16
cases of protoplasmic astrocytoma, and 7 cases of
oligodendroglioma), 56 cases were WHO III (including
42 cases of anaplastic astrocytoma and 14 cases of
anaplastic oligodendroglioma), and 29 cases were
WHO IV (all glioblastoma). Another 16 cases of normal
frontotemporal brain tissues under intracranial decom-
pression were collected from the First Affiliated Hos-
pital of the Guangxi Medical University as a control
group. Thirteen male and three female individuals were
enrolled in the study as healthy controls, with ages be-
tween 23 and 59 years old (with the median age of 48
and mean age of 43.75 ± 15.34). The clinical data was
obtained from the patients’ medical records and in-
cluded age, gender, and WHO grade.
Immunohistochemistry
Polyclonal antibody anti-CDK5 (sc-173, Santa Cruz Santa
Cruz Biotechnology Inc., CA, USA) and monoclonalantibodies Ki-67 (Beijing Zhongshan Jinqiao Inc., Beijing,
China) were used to perform the immunohistochemical
detection as previously described [17, 18]. To score CDK5
as immunopositive staining, the positive cells are shown
as a yellow to brown color of the nucleus and/or cyto-
plasm. One hundred cells from 10 representative regions
from each case were evaluated. The immunohistochemical
results were assessed based on the immunodetection of
stain intensity and number of positive cells. The results of
staining were evaluated by each author and an final agree-
ment regarding controversial cases was reached at a multi-
headed microscope. CDK5 expression was classified
semiquantitatively according to the following criteria: No
staining was recorded as 0; weak staining with focal or fine
granular morphology was considered as 1; linear or clus-
ter, strong staining was 2; and diffuse, intense staining was
considered as 3. As for the positive cells in each case, the
score ranged from 0 to 3 in percentage: 0 was when no
staining was observed, 1 presented as less than 30 % cells
were stained, and 2 was from 30 to 70 %. When more than
70 % cells were positive, it was recorded as 3. Finally, the
samples were categorized as positive and negative based
on the sum of the scores as follows: 0–2: negative, 3:
weakly positive (+), 4: moderately positive (++), and 5–6:
strongly positive (+++). Any score >3 was considered as
positive expression in the current study. For detection of
Ki-67 LI, the positive cells were shown as the distribution
in the nuclei. With the formula (number of positive cells/
total number of the cells × 100 %), the Ki-67 LI was calcu-
lated by observing at least 10 representative visions at high
magnification (40 × 10) [18, 17, 19].
Statistical analysis
For statistical analysis, SPSS 20 software was used. The
difference of CDK5 expression between two patient
subgroups was determined by using chi-square test.
Kruskal-Wallis H test was performed to detect the dif-
ferences between CDK5 expression and pathological
grades of glioma. The significance of difference of LI be-
tween two groups was analyzed by unpaired Student’s t
test. The statistical significance of the difference of LI
between more than two groups was assessed by using
ANOVA test. The predictive values of CDK5 and Ki-67
LI in diagnosis and tumor differentiation were evaluated
by the receiver operating characteristic (ROC) curves.
Spearman’s correlation was used to study the correl-
ation between CDK5 expression, Ki-67 LI, and tumor
grade. P values were two-sided, and significance level of
P < 0.05 was set up in all tests.
Results
Immunohistochemical location of CDK5 expression
Immunohistochemical staining results showed that CDK5
protein was expressed in glioma cell cytoplasm (Fig. 1).
Fig. 1 Expression of CDK5 in different grade glioma tissues. a WHO I glioma; b WHO II glioma; c WHO III glioma; d WHO IV GBM
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CDK5-positive expression (57.2 %) was higher in glioma
tissues than in normal brain tissues (12.5 %, Z = −3.400,
P = 0.001). The CDK5-positive expression in WHO III
glioma (62.5 %) and WHO IV glioma (82.8 %) was ob-
served to be higher when compared to WHO I glioma
(34.8 %; P = 0.026, P < 0.001, respectively, Fig. 2a). The
results disclosed a tendency of CDK5-positive ratio to
increase in high-grade glioma compared to low-grade
glioma (Z = −3.406, P = 0.001, Fig. 2b). The differences
among four grades were also statistically significant
(F = 15.482, P = 0.001, Table 1) as assessed by Kruskal-
Wallis H test. Spearman’s rank correlation confirmed
that CDK5 was positively correlated with the patho-
logical grade of glioma (r = 0.277, P = 0.001).
The relationship between CDK5 and Ki-67 LI
The result of Ki-67 LI was shown in Table 1. The glioma
tissues showed significantly higher Ki-67 LI than that
in normal brain tissues (11.41 ± 10.27 vs 0.61 ± 0.95,
P < 0.001). Ki-67 LI also showed significant differences
among the four WHO grades (P < 0.001, Fig. 2c). Ki-67 LI
was observed to be higher in high-grade glioma tissues
than in low-grade glioma tissues (18.79 ± 7.86 and 2.03 ±
1.87, P < 0.001, Fig. 2d). The significant correlation between
Ki-67 LI and the histological grade was found (r =
0.831, P < 0.001). The Ki-67 LI also showed a significant dif-
ference between CDK5-positive group and CDK5-negative
group (13.78 ± 10.61 vs 6.54 ± 8.41; P < 0.001, Fig. 3). Therewas a significant correlation for CDK5 expression and Ki-
67 LI in all tissues (r= 0.347, P < 0.001).
The predictive value of CDK5 for the occurrence and
progression in glioma
To investigate whether CDK5 expression levels have the
diagnostic value for glioma, ROC was performed. The
most notable finding was that CDK5 could be a signifi-
cant effect for diagnosing gliomas (AUC = 0.724, 95 %
confidence interval (CI) 0.610, 0.837; P = 0.003). CDK5
expression level significantly contributed to diagnosing
high-grade glioma (AUC = 0.666, 95 % CI 0.584, 0.749;
P < 0.001). The ROC curve indicated that Ki-67 LI ≥ 0.7
could significantly diagnose gliomas with 93.42 % sensi-
tivity and 75 % specificity and with AUC as 0.903 (95 %
CI 0.840, 0.967; P < 0.001, Fig. 4a). Additionally, the sig-
nificance also reached in the predictive effect of glioma
histological grade; Ki-67 LI as ≥7.5 could predict high-
grade WHO glioma (AUC = 0.982, 95 % CI 0.967, 0.998
with 91.76 % sensitivity and 98.5 % specificity, Fig. 4b).
Discussion
Glioma encompasses different histological subtypes with
high variability in prognosis and accounts for almost 80 %
of primary malignant brain tumors [20]. At present, the
causes for glioma tumorigenesis and aggressiveness re-
main unclear. Recently emerging researches have investi-
gated the expression of novel biomarkers in glioma. For
example, the hyper-methylation statuses of EGFR and
Fig. 2 The implication of CDK5 expression and Ki-67 LI in different tissues. a CDK5-positive expression was higher in glioma tissues than in normal
brain tissues (P = 0.002). The positive rate of CDK5 expression in WHO III and WHO IV was also significantly higher than in WHO I (P = 0.021, P = 0.020,
respectively); b CDK5 expression was significantly higher in high-grade gliomas than low-grade gliomas (P < 0.001); c the significant differences of Ki-67
LI among the different groups; d higher Ki-67 LI was detected in high-grade gliomas than in low-grade gliomas (P< 0.001). *P< 0.05;**P< 0.01;***P< 0.001
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been shown to play vital roles in glioma progression [21].
CDK5, one of the major kinases activated by its regu-
lators p35 or p39, directly phosphorylates various resi-
dues and simultaneously regulates various substrates [7].
Evidence indicates that CDK5 may have extra neuronal
functions that comprise transcript-selective translation
control, glucose-inducible insulin secretion, vascular
angiogenesis, cell adhesion, migration, and wound heal-
ing [22, 23]. Previous studies demonstrated that CDK5
overexpression was implicated in the tumorigenesis and
aggressiveness in several malignancies, for instance lung,
pancreatic, neuroendocrine thyroid, and breast cancer
[13, 12, 11, 10]. Similar results were achieved in our
current study that CDK5 expression was significantly
upregulated in gliomas tissues, as compared to normal
brain tissues. Further, our study found that CDK5 might
be a significant diagnostic factor for glioma with a large
population (n = 152) tested. Consistent with our study,
CDK5 expression was observed to be overexpressed in
NSCLC and breast cancer, which implies that CDK5
serves as an important role in the tumorigenesis of dif-
ferent malignancies [24, 25]. Evidence has shown that
CDK5 can downregulate the tumor suppressor DLC1
and target Dab1 and p53 in cancers, acting as a pro-
oncogenic factor [26–28]. Moreover, the increase of
CDK5 is involved in the pro-oncogenic pathways by tar-
geting Ral and FAK [11, 29]. CDK5 is also involved incell cycle of cancer by inactivating pRB [12]. With fur-
ther studies of CDK5, the researchers speculated the po-
tential roles of CDK5 in glioma. Tsai et al. were the first
to report that CDK5 protein and kinase activity were
lacking in a human GBM cell line [30]. Later, Gao et al.
identified that CDK5-T33 could suppress the change of
shape, loss of adhesion, and apoptosis that characterize
the response of U373 glioma cells to heat stress [31]. Re-
searchers have also found that CDK5 protein expression
is related with apoptosis in human glioblastoma multi-
forme [32]. In light of our study and previous reports,
we hypothesized that CDK5 may act as a pro-oncogenic
factor in gliomagenesis. However, additional functional
studies in vitro and in vivo are needed for the under-
standing of the role of CDK5 in gliomagenesis.
Further, we continued to investigate the relationship
between CDK5 expression and clinicopathological fac-
tors of gliomas, mainly the tumor grades. In the
current study, we observed that the increasing expres-
sion of CDK5 protein was significantly related to the
pathological grade in our set of 152 glioma cases. In
accordance with our study, Catania et al. conducted
the study that CDK5 expression in the astrocytomas
of grades II–IV was consistently stronger than that in
a single grade I pilocytic astrocytoma, which was the
first study to examine CDK5/p35 expression in hu-
man astrocytic tumors of varying grades. Neverthe-
less, the study only enrolled a small size of 12 human
Table 1 Association of CDK5 expression and Ki-67 LI with clinicopathological features
Parameters Total
(n)
Expression of CDK5 n (%) Z P Ki-67 relevant expression (2−ΔCq) t P
Negative Positive Mean ± SD
Tissue
Normal tissue 16 14 (87.5 %) 2 (12.5 %) −3.400 0.001 0.6062 ± 0.9518 −12.464 <0.001
Glioma 152 65 (42.8 %) 87 (57.2 %) 11.4053 ± 10.2714
Gender
Female 49 23 (46.9 %) 23 (53.1 %) −0.014 0.989 10.6449 ± 10.4964 0.216 0.829
Male 119 56 (47.1 %) 63 (52.9 %) 10.2664 ± 10.2259
Age (median)
≤41.5 84 34 (40.5 %) 40 (59.5 %) −1.695 0.09 11.5940 ± 10.6489 1.542 0.125
>41.5 84 45 (53.6 %) 39 (46.4 %) 9.1595 ± 9.8001
Grading1
I–II 67 39 (58.2 %) 28 (41.8 %) −3.406 0.001 2.0373 ± 1.8660 −18.988 <0.001
III–IV 85 26 (30.6 %) 59 (69.4 %) 18.7864 ± 7.85763
Grading2
I 23 15 (65.2 %) 8 (34.8 %) 15.482a 0.001 2.0000 ± 2.5045 104.022b <0.001
II 44 24 (54.5 %) 20 (45.5 %) 2.0568 ± 1.4609
III 56 21 (37.5 %) 35 (62.5 %) 17.4571 ± 7.3644
IV 29 5 (17.2 %) 24 (82.8 %) 21.3621 ± 8.2639
CDK5
Low 79 6.5380 ± 8.4147 −4.928 <0.001
High 89 13.7843 ± 10.6130
Ki-67 (median)
Low 84 54 (64.3 %) 30 (35.7 %) −4.469 <0.0001
High 84 25 (29.8 %) 59 (70.2 %)
aKruskal-Wallis H test was performed
bOne-way analysis of variance (ANOVA) test was used
Fig. 3 The comparison of Ki-67 LI between CDK5-positive and
CDK5-negative group. The CDK5-positive group revealed higher Ki-67
compared to the negative one (P < 0.001)
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that CDK5-mediated phosphorylation of PIKE-A could
activate AKT and enhance cell growth, as well as in-
duce glioblastomas cell migration and invasion [15].
Previous studies also confirmed that CDK5 might be
a critical player in cancer cell proliferation [12, 22].
CDK5 also showed to promote prostate cancer cell
growth through androgen receptor [33]. Pozo et al.
found that CDK5 was crucial for human medullary
thyroid carcinoma cell proliferation and thus it con-
tributed to the progression of medullary thyroid car-
cinoma [12]. Xu et al. also demonstrated that CDK5
and its two major binding partners, KIAA0528 and
FIBP, were required for breast cancer cell growth and
migration [22]. The important role of CDK5 in glioma
cell growth was also shown in the studies described previ-
ously by Liu et al. and Catania et al. [15, 32]. Add-
itionally, the strong correlation between CDK5
expression and Ki-67 LI was also found in our study,
which disclosed that CDK5 could be involved in gli-
oma cell proliferation. In support of the previous
Fig. 4 The ROC curves for the predicative value of Ki-67. a AUC of Ki-67 LI for diagnosing gliomas was 0.903 (95 % CI 0.840, 0.967; P < 0.001); b Ki-67 LI
as ≥7.5 could predict high-grade WHO glioma (AUC = 0.982, 95 % CI 0.967, 0.998; P = 0.008)
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multiple cellular processes and contribute to tumori-
genesis by promoting tumor proliferation and deteri-
oration in glioma.
Conclusions
Our results suggest that CDK5 may represent a valuable
predictive marker of tumorigenesis and progression in
glioma. Larger studies are still desirable in the future to
provide stronger evidence for CDK5 as a candidate diag-
nostic and prognostic biomarker of glioma.
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